Physician-led Advanced Therapeutic Plasma Exchange (TPE) protocols launch inside Cenegenics Beverly Hills, expanding access to personalized toxin reduction and biomarker-driven care in Southern California
BEVERLY HILLS, Calif., Feb. 27, 2026 /PRNewswire/ — MDLifespan (www.mdlifespan.com), a physician-led medical technology company and Public Benefit Corporation, today announced the launch of its Advanced Serial Therapeutic Plasma Exchange (TPE) protocols inside Cenegenics Beverly Hills.
The expansion brings MDLifespan’s structured, multi-session Advanced Therapeutic Plasma Exchange protocols to the Los Angeles market through a clinical integration with one of the country’s most recognized physician-led performance health centers.
Addressing Environmental Exposure in Southern California
Los Angeles residents face unique environmental stressors — from wildfire-related particulate exposure and urban air pollution to growing public awareness around microplastics, PFAS, and chemical contaminants in California water systems. As research continues to explore links between environmental toxins and systemic inflammation, more patients are seeking physician-directed strategies to evaluate and reduce circulating toxin burden.
The Cenegenics Beverly Hills integration strengthens MDLifespan’s position as a specialized provider of Advanced Serial Therapeutic Plasma Exchange protocols designed to help reduce inflammatory proteins and environmental toxins at the circulatory level.
“Southern California is a region where environmental exposure is part of the everyday health conversation,” said Dr. Paul Savage, Founder and Chief Medical Officer of MDLifespan. “Our Advanced Serial Plasma Exchange protocols are structured, physician-supervised plans designed to support measurable reductions in circulating inflammatory burden while integrating with advanced biomarker analysis.”
What This Launch Brings to the Los Angeles Market
Through this integration, Cenegenics Beverly Hills patients now have access to:
Therapeutic Plasma Exchange has historically been utilized in hospital settings for specific medical indications. MDLifespan adapts this established, minimally invasive medical technology into a standardized outpatient protocol model designed to address modern environmental exposure concerns within physician-led care environments.
Each protocol begins with advanced diagnostic testing to assess toxin burden and key biomarkers, followed by a series of plasma exchange sessions designed to support circulatory-level toxin reduction. Progress is monitored through objective laboratory data.
Integrating Precision Diagnostics with Structured Plasma Exchange
The collaboration reflects a broader evolution in personalized medicine — combining:
Rather than positioning plasma exchange as a single intervention, MDLifespan delivers a repeatable, protocol-driven model designed to integrate into established clinical infrastructures.
Supporting National Growth Through Strategic Clinical Partnerships
The Beverly Hills launch supports MDLifespan’s national expansion strategy, which centers on:
To learn more or schedule a consultation, visit: https://mdlifespan.com/cenegenics-consult
About MDLifespan
MDLifespan is a physician-led medical technology startup and certified Public Benefit Corporation delivering advanced detoxification and regenerative medicine solutions through Advanced Therapeutic Plasma Exchange. Founded by Dr. Paul Savage, MDLifespan focuses on removing environmental toxins and reversing chronic inflammation using clinically validated, personalized, and patented protocols.
About Cenegenics
Founded in 1997, Cenegenics is the global leader in performance health medicine and longevity. The company delivers personalized, physician-led programs grounded in comprehensive biomarker analysis, advanced diagnostics, evidence-based therapies, and continuous optimization.
View original content to download multimedia:https://www.prnewswire.com/news-releases/advanced-serial-plasma-exchange-arrives-in-beverly-hills-as-los-angeles-faces-rising-environmental-health-concerns-302699641.html
